# EmstoPA jobs and careers

> 0 open roles at EmstoPA as of October 23, 2026. Source: https://www.thejobsmap.com/company/emstopa

EmstoPA is developing a targeted biologic approach to address severe bleeding associated with excessive tissue plasminogen activator (tPA) activity. Elevated endogenous tPA levels are implicated in pathological hyperfibrinolysis and significant haemorrhage in settings such as cardiopulmonary bypass surgery and major trauma. In addition, administration of thrombolytic agents including tissue plasminogen activator, tenecteplase, and reteplase to treat acute vascular occlusions can result in serious bleeding complications. Current treatments for tPA-driven hyperfibrinolysis are non-specific and of limited effectiveness. Concerns regarding haemorrhagic risk have also contributed to cautious use of thrombolytic therapy in certain clinical settings. EmstoPA’s programme is focused on a humanised antibody fragment designed to specifically reverse tPA activity and manage tPA-associated bleeding in high-risk patients.

## Key facts

| | |
|---|---|
| Open roles | 0 |
| Headquarters | United Kingdom |
| Founded | 2017 |
| Employees | 1 to 10 |
| Industries | Biotechnology, Health Care, Manufacturing, Medical |
| Website | https://emstopa.com |

## Leadership

- Charles Phillips, Chief Executive Officer

## Common questions

### Is EmstoPA hiring right now?

EmstoPA has no open roles listed as of October 23, 2026. Roles appear here as soon as they are posted on EmstoPA's careers site.

### Where is EmstoPA headquartered?

EmstoPA is headquartered in United Kingdom and was founded in 2017.

### Who leads EmstoPA?

Charles Phillips, Chief Executive Officer, is at the top of EmstoPA's org chart.

### How do I apply for a job at EmstoPA?

Pick a role on EmstoPA's TheJobsMap page and select Apply. Every listing links to the original posting on EmstoPA's own careers site, so you apply directly with the employer.